Besides the well-known connections of the rare mutations in genes encoding for amyloid precursor protein (APP) and the presenilins (PS1 and PS2), a large body of evidence implies a crucial role for apolipoprotein E4 allele (ApoE4) in the risk of AD, e.g. recent integrative genomic analyses have described a distinct ApoE4-associated molecular pathway that promotes late-onset AD [
1]. Recent findings from large genome wide association studies (GWAS) have furthermore shown evidence for associations between common variants in a set of genes, among which CLU, CR1 and PICALM, and increased risk of sporadic AD [
2,
3], while next generation sequencing technologies and detailed bioinformatic analyses have furthermore identified novel rare variants [
4,
5]. Environmental factors such as a Mediterranean diet, physical exercise, and exposure to toxins have been associated with AD, and it is likely that environmental exposures during the entire lifespan interact with genetic susceptibility in bringing about AD in the elderly [
6]. Neuropathological, genetic and molecular biologic evidence has thus accumulated over the last years, and has given rise to a neurobiological theory on the cascade of events with central roles for alterations in the processing and metabolism of APP and tau protein, resulting in aggregates of beta-amyloid (Aβ) fibrils and neurofibrillary tangles. The Aβ cascade hypothesis has been fuelled with biochemical studies
in vitro and
in vivo studies on toxic properties of the different conformational and differently polymerized states of Aβ aggregates, particularly at the synaptic level [
7,
8], and has reached a more heuristic level with studies showing intricate crosstalk between misprocessing of beta-amyloid and tau proteins and neuroinflammation, ultimately disturbing neuronal and synaptic integrity and affecting cognitive functioning. A role for neuroinflammatory responses has been proposed in later phases of AD, but it has also been proposed that neuroinflammatory response act very early in the disease process by dysregulating mechanisms (for example at the level of the blood-brain barrier; [
9]) to clear misfolded or damaged neuronal proteins [
10,
11] and heavy metals [
12]. Based on recent studies indicating that dynamic changes in epigenetic regulation of gene expression is involved in many human (patho)physiological processes including experience-dependent plasticity, neurogenesis and aging, research efforts have been launched for studying epigenetic involvement in AD-associated neurodegeneration and disturbances of neuroplasticity, see e.g. [
13,
14]. Evidence from molecular and cellular studies have furthermore indicated that age-related changes in mitochondrial ATP production and oxidative stress are centrally involved in the pathophysiology of AD [
15], while evidence reviewed by Walter et al. in the current issue suggests that membrane lipids are involved in the regulation of subcellular transport, activity, and metabolism of AD-related proteins, and that vice versa, APP and other AD-associated proteins impact on lipid metabolic pathways [
16].